Current ratio of Tempus AI, Inc. Class A – HAN:F3M
The article focuses on the current ratio of Tempus AI, Inc. Class A (HAN:F3M) on the Hannover Stock Exchange. It provides a financial snapshot for the company, accessible through TradingView's platform, indicating that market data is provided by ICE Data Services and FactSet. The content is primarily a navigation and footer heavy page from TradingView, with little substantive article text.
A trading plan governed the sale of 10,281 Tempus AI (TEM) shares by its diagnostics CEO at $85 each.
Thomas Edward Schoenherr, CEO of Diagnostics at Tempus AI (TEM), sold 10,281 shares of Class A Common Stock at $85 per share on September 25, 2026. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 3, 2026. Following the sale, Schoenherr directly holds 76,740 shares.
Tempus AI, Inc. Class A Bonds — Corporate Bond Rates
This article lists corporate bond rates for Tempus AI, Inc. Class A, providing details on yield to worst, price, coupon, maturity date, outstanding amount, and face value for two different bonds. It serves as a resource for investors seeking stable investment options during market volatility.
Tempus AI receives FDA clearance for heart valve AI tool
Tempus AI has received 510(k) clearance from the U.S. Food and Drug Administration for its Tempus ECG-MR product. This AI tool analyzes standard 12-lead resting electrocardiograms to detect signs associated with undiagnosed moderate or severe mitral regurgitation. The company's portfolio now includes four FDA-cleared ECG-AI products, aiming to help identify high-risk patients for further evaluation.
Tempus AI CAO Ryan Bartolucci sells $529,650 in stock By Investing.com
Ryan Bartolucci, Chief Accounting Officer at Tempus AI, Inc., recently sold 7,062 shares of Class A Common Stock for $529,650, at a price of $75.00 per share. This sale was conducted under a Rule 10b5-1 trading plan adopted in June 2026, and after the transaction, Mr. Bartolucci directly holds 60,804 shares. The stock has since increased to $85.01, representing a 99% surge over the last six months, though InvestingPro analysis suggests the company may be overvalued.
Tempus AI EVP Andrew Polovin sells 2,951 shares for $221,325
Tempus AI EVP Andrew Polovin sold 2,951 shares of the company's Class A Common Stock for $221,325 on September 17, 2026, pursuant to a pre-arranged trading plan. Following the sale, Tempus AI's stock price increased, with InvestingPro suggesting it is overvalued. The company has recently received varied analyst ratings, including upgrades to Overweight from Piper Sandler and Cantor Fitzgerald, and a Neutral rating from Goldman Sachs and Rothschild Redburn.
Tempus AI CAO Ryan Bartolucci sells $529,650 in stock
Tempus AI's Chief Accounting Officer, Ryan Bartolucci, sold 7,062 shares of Class A Common Stock for $529,650 on September 17, 2026, through a pre-planned trading arrangement. Following this transaction, Bartolucci still holds over 60,000 shares. The sale occurred while the stock had surged 99% in six months, though InvestingPro analysis suggests the company is currently overvalued.
Form 144 Tempus AI For: 27 September By Investing.com
This article announces the filing of Form 144 for Tempus AI on September 27. It provides financial data for various global markets, including indices, commodities, and currencies, and features trending stocks and popular articles from Investing.com. The content focuses on market performance and news updates relevant to investors.
Tempus AI CEO-linked entities sell 250,000 shares
Entities linked to Tempus AI (TEM) CEO and Chairman Eric P. Lefkofsky sold a total of 250,000 Class A common shares on September 22, 2026. These indirect sales were conducted by Gray Media, LLC, Blue Media, LLC, Lefkofsky Family Foundation, and Vas.org Foundation, under a Rule 10b5-1 trading plan. The shares were sold at weighted-average prices ranging from $76.57 to $78.86 per share.
Tempus AI Chief Accounting Officer Sells $529,650 of Stock
Tempus AI's Chief Accounting Officer, Ryan M. Bartolucci, sold 7,062 shares of Class A Common Stock worth $529,650 on September 17, 2026, under a pre-arranged Rule 10b5-1 trading plan. Despite this sale, which represented a small percentage of his total holdings, he still retains 60,804 shares. The article notes that this transaction should not alarm investors, as the company has seen significant revenue growth, though it remains unprofitable.
Tempus AI chief accounting officer sells $529,650 in stock
Ryan M. Bartolucci, Tempus AI's Chief Accounting Officer, sold 7,062 shares of Class A common stock for $529,650 on September 17, 2026. This sale, executed via a Rule 10b5-1 trading plan, followed a significant 32% surge in the company's stock price over the past week. Despite the sale, Bartolucci still directly owns 60,804 shares, and the company has recently received positive analyst attention and price target increases due to its pending acquisition of Personalis.
Tempus AI (TEM) CAO sells stock in preset 10b5-1 trade
Tempus AI's Chief Accounting Officer, Ryan M. Bartolucci, sold 7,062 shares of Class A Common Stock at $75.00 per share on September 17, 2026. This sale was conducted under a Rule 10b5-1 trading plan adopted on June 5, 2026. Following the transaction, Bartolucci directly holds 60,804 shares.
EVP at Tempus AI (TEM) sells shares in preset plan trade
Tempus AI's EVP and Chief Legal Officer, Andrew Polovin, sold 2,951 shares of Class A Common Stock at $75.00 per share on September 17, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted in August 2025. Following the sale, Polovin directly holds 135,189 shares of TEM.
Tempus AI (TEM) data chief’s spouse sells 700 shares under plan
Ryan Fukushima, Tempus AI's CEO of Data, had his spouse sell 700 shares of Class A Common Stock at $70.00 per share on September 16, 2026. This transaction was executed under a Rule 10b5-1 trading plan established on March 12, 2026. Following the sale, Fukushima's indirect holdings through his spouse are 15,874 shares, while his direct holdings are 562,463 shares.
Tempus AI’s EVP, chief legal officer, sells $221,325 in stock By Investing.com
Tempus AI's Executive Vice President and Chief Legal Officer, Andrew Polovin, sold 2,951 shares of the company's Class A Common Stock for $221,325 on September 17, 2026, at a price of $75.0 per share. This sale was conducted under a Rule 10b5-1 trading plan. The stock has since increased by 32% to $77.84, with InvestingPro noting it as overvalued and highly volatile, while analysts have issued varied ratings and price targets following recent strategic developments, including the acquisition of Personalis.
Tempus AI’s EVP, chief legal officer, sells $221,325 in stock By Investing.com
Andrew Polovin, EVP and Chief Legal Officer at Tempus AI (TEM), sold 2,951 shares of Class A Common Stock for $221,325 on September 17, 2026. The sale was made through a Rule 10b5-1 trading plan adopted in August 2025. This transaction comes amidst recent analyst coverage and strategic developments for Tempus AI, including its acquisition of Personalis, which has led to varied price target adjustments and ratings from firms like H.C. Wainwright, Piper Sandler, and Cantor Fitzgerald.
Tempus AI CEO, data Ryan Fukushima sells $49,000 in stock By Investing.com
Tempus AI's CEO and Data, Ryan Fukushima, sold 700 shares of the company's Class A Common Stock for $49,000 on September 16, 2026, as part of a Rule 10b5-1 trading plan. Despite the sale, the stock saw a 31.9% gain in the past week, though InvestingPro deems it overvalued. The company has also received several positive analyst ratings and price target increases recently due to strategic acquisitions and advancements in genomic testing.
Tempus AI (TEM) CEO’s 200,000-share sale was preplanned
Tempus AI, Inc. CEO and Chairman Eric P. Lefkofsky sold 200,000 shares of Class A common stock on September 17, 2026, through affiliated entities. The sale, valued at approximately $16.11 million, was executed at weighted average prices between $80.00-$80.92 and $81.00-$81.26 per share. This transaction was preplanned under a Rule 10b5-1 trading plan adopted on March 8, 2026.
Could Tempus AI (NASDAQ:TEM) Change the NASDAQ AI Stocks Narrative?
Tempus AI (NASDAQ:TEM) is in focus after launching an initiative to build a large disease-specific whole-genome and clinical-outcomes dataset for AI-driven healthcare research. This development places commercial adoption of AI back in the spotlight, with market participants scrutinizing its impact on computing capacity, customer use, and deployment economics. The article emphasizes that consistent operational execution and clear disclosures will be crucial in demonstrating durable progress for Tempus AI amidst broader market concerns about inflation and interest rates.
Tempus AI (TEM) CEO's spouse sells 30,846 shares under trading plan
Tempus AI's CEO, Data Fukushima Ryan, reported an indirect sale of 30,846 Class A Common Stock shares through his spouse's account on September 1, 2026. These open-market transactions were executed under a pre-planned Rule 10b5-1 trading plan adopted on March 12, 2026. Following these sales, Fukushima Ryan directly holds 562,463 shares of Class A Common Stock.
Tempus AI Director Nadja West Sells 3,000 Shares for $207,000
Tempus AI Director Nadja West sold 3,000 shares of Class A Common Stock for $207,000 on August 28, 2026, according to an SEC filing. This transaction was part of a pre-established Rule 10b5-1 trading plan and represents 9% of her direct equity stake, leaving her with 31,981 shares. The company, a healthcare technology firm, is still in an investment phase, experiencing rapid revenue growth but also net losses.
Tempus AI Director Jennifer A. Doudna Sells 676 Shares Under Rule 10b5-1 Plan
Tempus AI Director Jennifer A. Doudna sold 676 shares of the company's Class A Common Stock at $65.55 per share on September 1, 2026. This transaction was conducted under a Rule 10b5-1 trading plan established in August 2025. After the sale, Doudna directly holds 25,266 shares of Tempus AI Class A Common Stock.
Tempus AI Data CEO Ryan Fukushima's Spouse Executes $30,846 Share Sale via 10b5-1 Plan
Ryan Fukushima, Tempus AI's CEO of Data, disclosed that his spouse sold 30,846 shares of Class A Common Stock on September 1, 2026, through a pre-established Rule 10b5-1 trading plan. The shares were sold in four tranches at weighted average prices between $62.12 and $64.63, totaling $30,846. Following these transactions, the indirect ownership by Fukushima's spouse decreased, while his direct holdings remained unchanged.
Tempus AI Director Nadja West Sells 3,000 Shares for $207,000
Nadja West, a Director at Tempus AI (NASDAQ:TEM), sold 3,000 shares of Class A Common Stock for $207,000 on August 28, 2026. This transaction was executed under a Rule 10b5-1 trading plan and represents 9% of her direct equity stake before the sale, leaving her with 31,981 shares. The article reassures investors that such sales are common and not indicative of acting on non-public information, especially given Tempus AI's continued rapid revenue growth despite current net losses.
Tempus AI Director Nadja West Sells 3,000 Class A Shares Under Rule 10b5-1 Plan
Tempus AI Director Nadja West sold 3,000 Class A Common Stock shares at $69 each on August 28, 2026, under a Rule 10b5-1 trading plan established on May 15, 2026. This transaction was disclosed in a Form 4 filed with the SEC on September 1, 2026. Following the sale, West directly holds 31,981 Class A shares of Tempus AI.
46,411 Shares in Tempus AI, Inc. $TEM Bought by Headlands Technologies LLC
Headlands Technologies LLC recently acquired 46,411 shares of Tempus AI (NASDAQ:TEM) worth approximately $2.69 million, despite mixed analyst sentiment and significant insider selling. Tempus AI reported better-than-expected quarterly earnings, with a loss of $0.04 per share against an estimated $0.14 loss, and revenue of $382.49 million, representing a 21.6% year-over-year increase. The stock currently holds an average "Hold" rating from analysts with a target price of $65.69, while insiders have sold over 1 million shares in the past 90 days.
Tempus AI CEO Eric Lefkofsky sells $827,856 in stock
Tempus AI CEO Eric P. Lefkofsky sold 11,848 shares of Class A Common Stock for $827,856 on August 25, 2026, as part of a pre-arranged trading plan. The sale occurred while the stock has seen significant gains, though InvestingPro analysis suggests it may be overvalued and highly volatile. The company recently reported a 22% revenue increase and a narrower-than-expected loss in Q2 2026, despite revised price targets from analysts.
Tempus AI (TEM) Earnings History & Trends
This article provides an overview of Tempus AI's (TEM) earnings history and trends, including its EPS and revenue performance against Street estimates. It highlights a 100% EPS beat rate and a 29.94% average EPS surprise, alongside quarter-by-quarter financial data from Q1 2025 to Q2 2026. The report also visualizes TEM's 30-day return after each earnings report compared to the S&P 500.
Tempus AI Data CEO Ryan Fukushima Sells 14,286 Shares via Spousal 10b5-1 Trading Plan
Ryan Fukushima, CEO of Data at Tempus AI, Inc. (NASDAQ:TEM), sold 14,286 shares of Class A Common Stock at $70 per share on August 21, 2026. This transaction was conducted under a Rule 10b5-1 trading plan established by his spouse on March 12, 2026. Following the sale, Fukushima indirectly owns 47,420 shares through his spouse and directly holds 562,463 Class A Common Stock shares.
Tempus AI (TEM) diagnostics CEO trades shares under 10b5-1 plan
Thomas Edward Schoenherr, CEO of Diagnostics at Tempus AI, Inc. (TEM), reported an insider transaction of 2,694 Class A Common Stock shares at $70.00 each on August 21, 2026. This transaction was executed under a Rule 10b5-1 trading plan adopted on March 3, 2026. Following the transaction, Schoenherr's direct holdings in the company's Class A Common Stock amount to 87,021 shares.
Tempus AI (TEM) exec's spouse sells 14K shares under preset plan
The spouse of Tempus AI's CEO of Data, Ryan Fukushima, sold 14,286 shares of Class A Common Stock at $70.00 per share on August 21, 2026, totaling $1.00 million. This transaction was executed under a Rule 10b5-1 trading plan adopted on March 12, 2026. Following the sale, indirect holdings by his spouse are 47,420 shares, and Ryan Fukushima directly holds 562,463 shares.
Tempus AI Insiders Sold Stock Through Pre-Set Plans Before 75% Rally
Three Tempus AI insiders sold over $2.7 million in company stock through pre-arranged Rule 10b5-1 trading plans just as the company's shares rallied by 75%. This surge was driven by positive cancer vaccine trial results from Moderna and Merck, validating technology crucial to Tempus AI's acquisition of Personalis. Despite the sales raising investor interest, their pre-scheduled nature suggests they were not opportunistic, and the company reported strong Q2 revenue and its first GAAP profit.
ETFs Investing in Tempus AI, Inc. Class A Stocks
This article lists various Exchange Traded Funds (ETFs) that hold Tempus AI, Inc. Class A stocks, sorted by market value. It provides details for each ETF, including market value, weight of Tempus AI stock, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, relative volume, and 3-year NAV total return. The information aims to help investors find accessible and lower-risk opportunities for investing in Tempus AI through diversified funds.
Tempus AI's Diagnostics Chief Filed Stock Sales Spanning a Volatile Week. Here's What Happened
Thomas Edward Schoenherr, CEO of diagnostics at Tempus AI (NASDAQ: TEM), sold 17,314 shares of Class A Common Stock across August 18 and 19 for approximately $930,000. These sales were part of a pre-established Rule 10b5-1 trading plan to cover tax withholding obligations from restricted stock unit vesting, not a discretionary move after the stock's recent volatility. Schoenherr retains a significant stake, and the company emphasized that the scheduled sale during a volatile week should not deter long-term investors from focusing on performance.
A Tempus AI Director Sold Stock Four Days Before a 24% Rally. Here's What to Know
A director at Tempus AI, Nadja West, sold 3,000 shares of Class A Common Stock on August 14 under a pre-established 10b5-1 trading plan, four days before the stock saw a significant rally. The sale, valued at $161,700, was a routine divestment and represented a small portion of her total holdings, with West still retaining a substantial direct ownership stake. Investors should focus on the company's strong second-quarter revenue growth and its pending acquisition of Personalis, which is driving current market excitement, rather than this scheduled insider transaction.
Tempus AI diagnostics CEO sells nearly $930k in stock
Thomas Edward Schoenherr, CEO of Diagnostics at Tempus AI, recently sold 17,314 shares of the company's Class A Common Stock for approximately $929,989. These sales occurred on August 18 and 19, 2026, amid a 28% stock surge. One transaction was for tax withholding, while the other was executed under a Rule 10b5-1 trading plan.
Tempus AI EVP, chief legal officer Polovin sells $1.54m in stock
Andrew Polovin, EVP and Chief Legal Officer of Tempus AI (NASDAQ:TEM), sold 30,075 shares totaling approximately $1.54 million across two transactions on August 18 and 19, 2026. One sale was to cover tax obligations from vested restricted stock units, while the other was part of a pre-planned trading strategy. These sales occurred as Tempus AI stock surged 28% over the prior week, leading to concerns about overvaluation, and follow the company's recent Q2 2026 financial results which saw a narrower loss but a revenue miss.
Tempus AI CFO James Rogers sells $2.69m in stock
Tempus AI's CFO, James Rogers, sold approximately $2.69 million worth of Class A Common Stock in mid-August through two transactions. One sale covered tax withholding obligations, while the other was part of a Rule 10b5-1 trading plan. These sales occurred as the stock surged 28% and is considered overvalued by InvestingPro.
Tempus AI chief accounting officer sells $306,341 in shares
Tempus AI's Chief Accounting Officer, Ryan M. Bartolucci, sold 6,175 shares worth $306,341 to cover tax withholding obligations. This sale occurred on August 18, 2026, and was not a discretionary transaction. The company's stock has since risen significantly, despite recent mixed financial results and revised price targets from analysts.
Tempus AI (NASDAQ: TEM) CAO sells shares in tax-cover move
Tempus AI (NASDAQ: TEM) Chief Accounting Officer Ryan M. Bartolucci sold 6,175 shares of Class A Common Stock on August 18, 2026, at a weighted average price of $49.61 per share. This transaction was a mandatory "sell to cover" to satisfy tax withholding obligations upon the vesting of restricted stock units, not a discretionary sale. After the sale, Bartolucci directly holds 67,866 shares of Tempus AI Class A Common Stock.
Tempus AI, Inc. Class A Revenue Breakdown – FWB:F3M
Tempus AI, Inc. (FWB:F3M) generated 1.08 billion EUR in revenue last year, with its Genomics segment being the top performer, contributing 813.43 million EUR. The United States was the primary geographic contributor, accounting for the entire 1.08 billion EUR in revenue.
Tempus AI (TEM) CEO offloads shares to cover RSU taxes owed
Tempus AI (TEM) CEO and Chairman Eric P. Lefkofsky sold 132,591 shares of Class A Common Stock on August 18, 2026, at a weighted average price of $49.61 per share. This sale was mandated to cover statutory tax withholding obligations from RSU vesting and was not a discretionary transaction. Following the sale, Lefkofsky retains significant direct and indirect holdings in the company.
Tempus AI (TEM) CFO unloads 48,842 shares via tax cover and plan
Tempus AI (TEM) CFO James William Rogers sold a total of 48,842 shares of Class A Common Stock across two days in August 2026. This included 22,529 shares sold to cover statutory tax withholding obligations on RSU vesting, and 26,313 shares sold under a pre-arranged Rule 10b5-1 trading plan. These sales are detailed in a Form 4 SEC filing, with specific prices and dates for each transaction.
Tempus AI (TEM) legal chief sells 30K shares via tax cover and 10b5-1 plan
Tempus AI's EVP and Chief Legal Officer, Andrew Polovin, sold a total of 30,075 shares of Class A Common Stock across two transactions in August 2026. The sales included 22,148 shares to cover tax withholdings on vested restricted stock units and 7,927 shares under a Rule 10b5-1 trading plan. The transactions totaled approximately $1.54 million.
Tempus AI (TEM) exec’s 17K share sale blends taxes and 10b5-1 plan
Thomas Edward Schoenherr, CEO of Diagnostics at Tempus AI (TEM), sold a total of 17,314 shares of Class A Common Stock across seven transactions on August 18-19, 2026. A block of 9,232 shares was sold to cover tax withholding obligations upon the vesting of restricted stock units, which was not a discretionary sale. The remaining sales were executed under a Rule 10b5-1 trading plan established on March 3, 2026.
Tempus AI (TEM) insider's tax sale and remaining stake
Tempus AI (TEM) officer Ryan Fukushima sold 41,095 shares of Class A Common Stock for $49.61 per share on August 18, 2026. This transaction was a mandatory "sell to cover" to satisfy tax withholding obligations from restricted stock unit vesting and was not a discretionary sale. Following this, Fukushima directly holds 562,463 shares and indirectly holds 61,706 shares through his spouse.
Ryan Fukushima, CEO, sells $2.04m in Tempus AI stock
Tempus AI CEO Ryan Fukushima sold 41,095 shares of Class A Common Stock for approximately $2.04 million on August 18, 2026. This transaction was a "sell to cover" for tax obligations related to restricted stock units, not a discretionary sale. The stock has since seen a significant surge, and the company recently reported Q2 2026 revenue growth and ongoing strategic developments including acquisitions and analyst rating adjustments.
Tempus AI Inc Stock (TEM) Moved Up by 10.87% on Aug 20: What Signal Does It Send?
Tempus AI Inc (TEM) saw its stock rise by 10.87% on August 20, driven by positive Phase 3 trial results for individualized mRNA cancer vaccines from Merck and Moderna, which validated Tempus AI's acquisition of Personalis. The stock also benefited from a reaffirmed Buy rating and raised price target from BTIG Research, strong quarterly earnings, and a short squeeze due to elevated short interest. However, the company faces risks such as equity dilution from the Personalis acquisition, insider stock liquidation, negative free cash flow, and analyst valuation caps.
Tempus AI CEO Sells 133,000 Shares Ahead of Stock Surge
Tempus AI CEO Eric P. Lefkofsky sold 133,000 shares for $6.6 million to cover tax obligations, a non-discretionary sale not reflecting his market outlook. Following this, Tempus AI's stock surged significantly due to positive Phase 3 melanoma trial results from Moderna and Merck, validating Tempus's genomic sequencing technology and acquisition strategy. The company also reported its first GAAP profit in Q2 with revenue up 22%, raising its full-year guidance, indicating strong market demand and growth potential.
Tempus AI (TEM) exec's $2.1M stock sale tied to tax withholding
Tempus AI (TEM) officer Ryan Fukushima has filed a Rule 144 notice for the potential sale of 41,095 shares of Class A common stock, valued at approximately $2.1 million. The company clarified that this sale is a mandatory "sell to cover" transaction to satisfy tax withholding obligations under its equity incentive plan, not a discretionary trade. The filing also notes previous 10b5-1 sales by another participant, Vanessa Kubo.
